Key facts
- It has raised $3.5M; the latest was Early Stage VC ($3.5M) in May 2025.
- Notable investors include HB Investment, LSK Investment.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for GluGene Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for GluGene Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GluGene Therapeutics
Developer of gene therapy technologies designed to enhance the performance and versatility of adeno-associated virus vectors. The company engages in the production of assembled, directed evolution, and machine learning-based AAV engineering with adhesive molecule assembly to address the limitations of existing technology, enabling biopharmaceutical researchers to achieve organ-specific delivery, antibody resistance, and expanded therapeutic payloads for advanced genetic medicines.
- Sector
- Healthcare
- HQ
- Daejeon, South Korea
- Founded
- 2021
- Employees
- 11
- Website
- glugene.com/
- Ownership
- Privately Held (backing)
GluGene Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GluGene Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GluGene Therapeutics in its N-PORT filings yet. We sweep new filings monthly.